Mei Pharma Inc (MEIP)

$3.06 0.04 (1.29%)

13:20 EDT MEIP Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Dec 6, 2022

Good morning, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

More Articles

Volume:

Previous Close -

Market Cap 20.39M

PE Ratio 38.25

EPS 0.08

Volume (Avg. Vol.) 5,886

Day's Range $3.03 - $3.15

52-Week Range $3.10 - $7.97

Dividend & Yield N/A (N/A)

MEIP Stock Predictions, Articles, and Mei Pharma Inc News

From InvestorPlace
From the Web

Penny Stocks Today: Why MEIP and HNST Are Plunging Friday

By William White, InvestorPlace Writer Mar 25, 2022

We're checking in on the latest penny stocks news for today with two companies that investors are watching fall on Friday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Mar 25, 2022

Good morning, trader! Get ready for one more busy day of investing today with the biggest pre-market stock movers for Friday!

37 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 26, 2016

This week, the overall grades of 37 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

52 Biotechnology Stocks to Sell Now

By Portfolio Grader Nov 14, 2016

The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

27 Biotechnology Stocks to Sell Now

By Portfolio Grader Nov 7, 2016

This week, 27 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

13 Biotechnology Stocks to Buy Now

By Portfolio Grader Aug 22, 2016

The grades of 13 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

Hottest Manufacturing Stocks Now – MEIP PRAN LPTH ONVO

By Portfolio Grader Aug 8, 2016

The following stocks were the biggest movers and shakers in the Manufacturing sector today.

41 Biotechnology Stocks to Sell Now

By Portfolio Grader Jul 25, 2016

The overall ratings of 41 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

MEI Pharma files for $100M mixed shelf (NASDAQ:MEIP)

From Seeking Alpha Feb 20, 2024

MEI Pharma files prospectus for mixed securities shelf offering of up to $100M.

Infinity Pharmaceuticals reportedly files for Chapter 11 (OTCMKTS:INFI)

From Seeking Alpha Sep 29, 2023

Infinity Pharmaceuticals (INFI) has reportedly filed for bankruptcy in the wake of the termination of its merger deal with MEI Pharma.

MEI Pharma postpones special meeting to vote on Infinity deal until July 23

From Seeking Alpha Jul 13, 2023

MEI Pharma Inc. (MEIP) postponed a special meeting for holders to vote on its merger with Infinity Pharmaceuticals (INFI). The holder vote was postponed to July 23 from a scheduled vote...

Proxy advisor ISS recommends MEI, Infinity shareholders approve merger (NASDAQ:MEIP)

From Seeking Alpha Jul 5, 2023

Institutional Shareholder Services has recommended that MEI Pharma (MEIP) and Infinity Pharmaceuticals (INFI) shareholders vote in favor of their planned merger. Read more here.

Spurned MEI Pharma suitors call rejection 'derogation of duties'

From Seeking Alpha Jun 1, 2023

Two private equity firms whose bid for MEI Pharma was rejected by the company board called the rejection a complete derogation of its fiduciary duties. Read more here.

Brookline Capital Markets Remains a Buy on MEI Pharma (MEIP)

From TipRanks Dec 6, 2022

In a report released yesterday, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on MEI Pharma (MEIP – Research Report), with a ...

ADVERTISEMENT